HC Wainwright Reiterates Buy Rating for Oncolytics Biotech (NASDAQ:ONCY)

HC Wainwright reissued their buy rating on shares of Oncolytics Biotech (NASDAQ:ONCY) in a research note issued to investors on Monday,Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright also issued estimates for Oncolytics Biotech’s FY2029 earnings at $0.73 EPS.

Several other research analysts also recently weighed in on ONCY. Leede Financial downgraded shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a report on Wednesday, November 13th. Royal Bank of Canada lowered their price objective on Oncolytics Biotech from $6.00 to $5.00 and set an “outperform” rating on the stock in a research report on Monday. Finally, Raymond James upgraded Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday, November 14th. Three investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $4.00.

Oncolytics Biotech Trading Up 2.8 %

Shares of NASDAQ:ONCY opened at $0.63 on Monday. The stock has a 50 day moving average of $0.77 and a 200 day moving average of $0.92. The company has a market cap of $53.87 million, a PE ratio of -2.33 and a beta of 1.18. Oncolytics Biotech has a 12-month low of $0.58 and a 12-month high of $1.53.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ONCY. Vantage Point Financial LLC purchased a new position in shares of Oncolytics Biotech in the fourth quarter valued at $27,000. National Bank of Canada FI lifted its position in Oncolytics Biotech by 199.6% during the fourth quarter. National Bank of Canada FI now owns 64,479 shares of the company’s stock valued at $60,000 after purchasing an additional 42,955 shares during the last quarter. Geode Capital Management LLC lifted its position in Oncolytics Biotech by 59.6% during the fourth quarter. Geode Capital Management LLC now owns 66,939 shares of the company’s stock valued at $61,000 after purchasing an additional 24,997 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Oncolytics Biotech in the 4th quarter worth $90,000. Finally, International Assets Investment Management LLC increased its holdings in shares of Oncolytics Biotech by 15.0% in the 4th quarter. International Assets Investment Management LLC now owns 200,400 shares of the company’s stock worth $186,000 after buying an additional 26,069 shares during the last quarter. Hedge funds and other institutional investors own 6.82% of the company’s stock.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.